Leidi.com Lei Jianping July 19
Shaanxi Hanwang Pharmaceutical Co., Ltd. (abbreviation: "Hanwang Pharmaceutical") recently had its IPO terminated.
Hanwang Pharmaceutical once planned to be listed on the main board of the Shanghai Stock Exchange, and planned to raise 483 million yuan, of which 350 million yuan was used for the relocation project of the modern Chinese medicine production base, 48.28 million yuan was used for the upgrading and construction project of the marketing channel network, and 80 million yuan was used for the supplementary working capital project.
Annual revenue of 752 million
Since its establishment, Hanwang Pharmaceutical has been mainly engaged in the R&D, production and sales of Chinese patent medicines. Its main products cover cardiovascular and cerebrovascular systems, hepatobiliary, rheumatic orthopedics, digestive system, respiratory system and other fields.
According to the prospectus, the revenue of Hanwang Pharmaceutical in 2020, 2021 and 2022 will be 708 million yuan, 730 million yuan, and 752 million yuan respectively; the net profit will be 179 million yuan, 182 million yuan, and 260 million yuan;
In 2020, 2021 and 2022, Hanwang Pharmaceutical’s government subsidies included in the current profit and loss are 20.594 million, 21.166 million and 11.2246 million respectively, accounting for 9.65%, 9.78% and 3.64% of the total profit for the current period.
Feng Zhenbin and his wife control 54% of the shares
The actual controllers of Hanwang Pharmaceutical are Feng Zhenbin and Zhang Juxia.
Feng Zhenbin directly holds 17,119,800 shares of Hanwang Pharmaceutical, with a shareholding ratio of 4.75%; Feng Zhenbin and Zhang Juxia jointly hold 100% of the shares of Senhan Industrial, and Senhan Industrial holds 133,745,000 shares of Hanwang Pharmaceutical, with a shareholding ratio of 37.15%;
Hanbang Huijin holds 43,542,500 shares of Hanvon Pharmaceuticals, with a shareholding ratio of 12.1%. Feng Zhenbin holds 79.29% of the capital contribution of Hanbang Huijin, and indirectly controls the 12.1% shares of the company held by Hanbang Huijin by serving as the executive partner of Hanbang Huijin.
Feng Zhenbin and Zhang Juxia jointly actually control 54% of the company's shares and are the joint actual controllers of the company. Feng Zhenbin is the chairman and general manager of the company.
Before the IPO, Hanjiang Group held 30.08% of the shares, Hanzhong State-owned Assets Supervision and Administration Commission (SS) held 11.5% of the shares, Wang Zhengjun, vice chairman of Hanwang Pharmaceutical, held 3.12% of the shares, and Wu Chunyang and Xu Lanxuan held 0.65% of the shares respectively.
After the IPO, Senhan Industrial holds 33.43%, Hanjiang Group holds 27.06%, Hanbang Huijin holds 10.88%, Hanzhong State-owned Assets Supervision and Administration Commission (SS) holds 10.35%, Feng Zhenbin directly holds 4.28%, Wang Zhengjun holds 2.81%, and Wu Chunyang and Xu Lanxuan hold 0.58% respectively.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
